Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.51, $0.17 better than the analyst estimate of $0.34. Revenue for the quarter came in at $22.9 million versus the consensus estimate of $21.65 million.

“The solid results we delivered in the second quarter demonstrate accelerating demand, which combined with our tangible pipeline progress, positions Anika to deliver robust growth for many years,” stated Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “As in recent quarters, physician and patient demand for our homegrown orthobiologics products continued to gain traction, and was the highlight of our commercial results. We expect that trend to continue with the launch of two important orthopedic products in the coming years, which will provide an important catalyst for additional value creation.”

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.